Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1 - Haag, Georg Martin; Zörnig, Inka; Hassel, Jessica C.; Halama, Niels; Dick, Julika; Lang, Nina; Podola, Lilli; Ziegelmeier, Claudia; Freitag, Angelika; Beckhove, Philipp; Enk, Alexander; Jäger, Dirk (European journal of cancer, 2018)
Gesehen am 15.08.2019